BioSpace News Archive

Evotec SE presents at its virtual Capital Markets Day how artificial intelligence and machine learning enabled precision technologies in discovery and development processes are driving up Probability of Success, i.e. an increasing rate of approvals in the long-run.

Prokarium announced it exercised its option with Lausanne University Hospital for an exclusive, worldwide license for the use of Salmonella immunotherapy in the treatment of bladder cancer.

GC Labs, the leading clinical diagnostics company in Korea, announced the new lab testing service agreement with two partners: Bio Lab in Bahrain and Biotrust in Cambodia.

RedCloud Bio, an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug development, announced that the US Food and Drug Administration has accepted the Company’s Investigational New Drug application, clearing the path to proceed Phase I/IIa clinical investigation of H002, a broad spectrum, highly selective, fourth-generation compound.

ALX Oncology Holdings Inc. today announced the first patient has been dosed in the Phase 2/3 ASPEN-06 study evaluating the combination of evorpacept, a next generation CD47 blocker, and CYRAMZA ® (ramucirumab).

Jounce Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 17 newly-hired employees stock options to purchase an aggregate of 228,000 shares, and restricted stock units covering an aggregate of 62,000 shares, of BioCryst common stock.

Akari Therapeutics, Plc, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems are implicated, announced the appointment of Rachelle Jacques as President and Chief Executive Officer of Akari Therapeutics.

Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will be participating in a Cell Therapy Panel at the Cowen 42nd Annual Health Care Conference.

Seegene Inc. today announced the appointment of Richard S. Creager, Ph.D., as the CEO of its United States subsidiary, Seegene Technologies.